Purinergic signalling and disorders of the central nervous system.
NAT REV DRUG DISCOV
575 - 590.
Purines have key roles in neurotransmission and neuromodulation, with their effects being mediated by the purine and pyrimidine receptor subfamilies, P1, P2X and P2Y. Recently, purinergic mechanisms and specific receptor subtypes have been shown to be involved in various pathological conditions including brain trauma and ischaemia, neurodegenerative diseases involving neuroimmune and neuroinflammatory reactions, as well as in neuropsychiatric diseases, including depression and schizophrenia. This article reviews the role of purinergic signalling in CNS disorders, highlighting specific purinergic receptor subtypes, most notably A(2A), P2X(4) and P2X(7), that might be therapeutically targeted for the treatment of these conditions.
|Title:||Purinergic signalling and disorders of the central nervous system|
|Keywords:||ADENOSINE A(2A) RECEPTORS, EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS, TRANSIENT FOREBRAIN ISCHEMIA, ALZHEIMERS-DISEASE PATIENTS, ACTIVATED PROTEIN-KINASE, CORTEX KINDLED SEIZURES, TEMPORAL-LOBE EPILEPSY, TRANSGENIC MOUSE MODEL, RAT HIPPOCAMPAL SLICES, SPINAL-CORD-INJURY|
|UCL classification:||UCL > School of Life and Medical Sciences
UCL > School of Life and Medical Sciences > Faculty of Life Sciences
UCL > School of Life and Medical Sciences > Faculty of Life Sciences > Biosciences (Division of)
Archive Staff Only